

Supplementary Material and Methods

Combinatory treatment with lenalidomide and ibrutinib

Cells were seeded and treated with 0.3 μM cytarabine, 0.01 μM bortezomib or 0.1 μM lenalidomide, alone or in combination with each other. Duplicates from each concentration were counted in an automatic cell counter (CountessTM, Invitrogen) at each time point, and trypan blue exclusion method was used to monitor viability. Lysates for RT-qPCR and immunoblotting was sampled after 24 and 48 hours of growth. No significant differences could be observed in any of the sub clones and no synergy effects could be observed when combining lenalidomide and bortezomib (data not shown).

Vector Information DCK OmicsLinkTM Expression Clone (EX-C0081-M46)

